Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Glecaprevir/ Pibrentasvir in a real-world cohort of chronic hepatitis C in all major genotypes (GT1-6): Spanish real-life cohort (Hepa-C registry)

Next Previous
Search
Trial Profile

Efficacy and safety of Glecaprevir/ Pibrentasvir in a real-world cohort of chronic hepatitis C in all major genotypes (GT1-6): Spanish real-life cohort (Hepa-C registry)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 29 Aug 2020 Interim Results (n=114) from real-world Spanish Hepa-C registry, assessing effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment naive hepatitis C patients with liver cirrhosis, presented at The International Liver Congress 2020
    • 10 Dec 2018 New trial record
    • 13 Nov 2018 Interim results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top